Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

Crucell Terug naar discussie overzicht

RT Donderdag 27 december

120 Posts
Pagina: «« 1 2 3 4 5 6 | Laatste | Omlaag ↓
  2. aossa 28 december 2006 22:59

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.621

    Wat ze in die fabrieken gaan neerplanten om op grote schaal te kunnen produceren gaan ze nu uitvinden tesamen met (bmv technologie) Merck&Co.
  3. [verwijderd] 28 december 2006 22:59

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    flosz schreef:

    [quote=Baar]
    [quote=oudje]
    Arie, Crucell heeft fabrieken in Nederland, Zwitserland, Korea en Spanje.
    [/quote]

    Zelfs in de USA....binnenkort met DSM!
    [/quote]
    Linkje erbij...(lol)
    www.percivia.com
    Kijk Flosz!

    Hier krijg ik het nou helemaal warm van!

    Aanbevolen!

    Heb je nog meer van deze leuke plaatjes????? Plaatjes zeggen meer dan 1000 woorden (die op 36 verschillende manieren uitgelegd/geinterpreteerd kunnen worden)
  4. [verwijderd] 28 december 2006 23:00

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    aossa schreef:

    Wat ze in die fabrieken gaan neerplanten om op grote schaal te kunnen produceren gaan ze nu uitvinden tesamen met (bmv technologie) Merck&Co.
    WOOOOOWWW

    KICKEEEEENNNN!!!!! Wat een super building is dit zeg!!!!

    Arie is weer helemaal blij!

    AB Aossa!

    Wat denk JIJ trouwens wat het aandeel de komende tijd gaat doen?

    Op de dag van de terugslag (4 weken terug tijdens de meeting) zat jij het er het beste mee in de buurt!
  6. [verwijderd] 28 december 2006 23:03

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    jan941 schreef:

    Mooi gebouw Flosz,
    Hoeveel van die 20.000 liter dingen passen erin
    Ik hoop 200.000 :)

    DSM and Crucell celebrate opening of PERCIVIA PER.C6®
    Development Center in Cambridge, Massachusetts (USA)08-Nov-2006

    En hij is al reeds geopend....

    Wat hoor je daar toch weinig van evengoed ik dacht nog een paar weken te gaan!
  7. [verwijderd] 28 december 2006 23:04

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Life at PERCIVIA
    PERCIVIA is focused on providing our employees with an exciting, dynamic work environment combined with learning and career advancement opportunities.

    PERCIVIA offers employees an open and entrepreneurial environment where they can grow in their careers and gain valuable industry knowledge and experience. We strive to provide competitive benefits and compensation to our employees, and we monitor the market and the company to address changes in employee needs.

    PERCIVIA has a new and exciting atmosphere, where employees can make a direct impact on the organization and share in the success of a growing company.

    Job Postings

    Associate Scientist I, II, and III, Upstream Process Development

    Description:
    Work with teams of scientists and engineers to develop and optimize cost effective and scaleable cell culture processes for the production of recombinant proteins. Assist in the design and execution of experiments at the bench and pilot scale; help formulate recommendations to improve quality, productivity, and efficiency. Contribute to the preparation of development and technical reports and other project documentation.

    Experience:
    B.S. or M.S. in Biochemical Engineering, Chemical Engineering, Mechanical Engineering, or Life Sciences. Prior experience with mammalian cell culture is a plus. Prior experience with mammalian cell culture process development is a prerequisite for AS II and III positions.

    Scientist I, II, and III, Upstream Process Development

    Description:
    Work with teams of scientists and engineers to develop and optimize cost effective and scaleable cell culture processes for the production of recombinant proteins. Provide technical support and guidance for the design, development, scale-up, optimization, monitoring, and/or operation of robust, cost effective, and scaleable processes. Design and conduct necessary experiments with minimal oversight; interpret results; recommends changes or additional experiments to improve quality, productivity, and overall efficiency of the process. Implement project plans. May lead small project teams and technology transfer efforts between groups/organizations. Provide technical guidance and training to less experienced staff.

    Experience:
    Ph.D. in Biochemical Engineering, Chemical Engineering, Mechanical Engineering, or similar with emphasis in life sciences. M.S. with multiple years relevant experience will also be considered. Prior experience with mammalian cell culture is a prerequisite. Experience in industrial cGLP/cGMP environment is a plus. Prior supervisory experience is desired for Sci II and III positions.

    Associate Scientist I, II, and III, Downstream Process Development

    Description:
    Work with teams of scientists and engineers to develop and optimize cost effective and scaleable purification processes for the production of recombinant proteins. Assist in the design and execution of experiments at the bench and pilot scale; help formulate recommendations to improve quality, productivity, and efficiency.

    Experience:
    B.S. or M.S. in Biochemical Engineering, Chemical Engineering, Mechanical Engineering, or life sciences. Prior experience with protein purification is essential. Prior experience with recombinant protein downstream process development is a prerequisite for AS II and III positions.

    Scientist I, II, or III, Downstream Process Development

    Description:
    Work with or lead teams of scientists and engineers to develop and optimize cost effective and scaleable purification processes for the production of recombinant proteins. Design procedural and experimental approaches to meet objectives. Execute experiments, interpret results, and recommend changes or additional experiments to improve quality, productivity and efficiency of the process. Implement project plans and ensure completion within specified timelines. Manage multiple priorities and tasks. Provide technical guidance and training to less experienced staff. Interact with senior external personnel on significant technical matters often requiring coordination between organizations. Represent the corporation the greater biotech community by publishing in peer review journals and participating in scientific/technical conferences.

    Experience:
    Ph.D. in Biochemical Engineering, Chemical Engineering, Mechanical Engineering, or life sciences with 1 to 7 years of experience depending on the level. Prior experience with recombinant protein downstream process development is a prerequisite for all positions. Experience in the Biotechnology industry is highly preferable. Expertise in Technology Transfer and knowledge of cGMP is a plus.
    How to Apply
    PERCIVIA has just opened its new research and development facility in Kendall Square, the heart of the biotechnology community in Cambridge, Massachusetts. If you want to learn more about the company and/or become part of this dynamic organization, we would like to hear from you. We invite you to review our current list of career opportunities. Should you see something you are interested in and qualified for, or just want to ask a question, please send your resume or CV and a cover letter by email to the following address. Word documents are preferred.
  10. aossa 28 december 2006 23:08

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.621

    quote:

    Baar schreef:

    Wat denk JIJ trouwens wat het aandeel de komende tijd gaat doen?
    Ik dacht dat jan07 een zwakke maand zou worden in afwachting van Q4-cijfers in feb07. Zwakke maand betekent dat de drukkers en de shorters feest vieren.

    Heb me dus voorbereid op nog wat lagere koersen. Maar eerlijk gezegd met het recente nieuws begin ik te twijfelen. Heb me in ieder geval aan de veilige kant gesteld en (bijna) volledig long. Kleine shortpositie veilig gesteld met een cover. Verwacht in ieder geval na half feb07 een grote sprong opwaarts. Maar men kan nooit weten ...
  12. [verwijderd] 28 december 2006 23:08

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Aossa!

    Thxxx

    Heh! eerst was Crucell nog leuk...nog een beetje bij te houden qua PB's lekkere oplopende koersen.....vandaag te dag gaat het allemaal veel te snel qua MEER DAN POSITIEVE ontwikkelingen en de koers te langzaam....

    Je hoort helemaal niets over dat gebouw en de ontwikkelingen in de States waarvan ik dus dacht dat het nog niet eens geopend was....anderhalve maand geleden al....ahum!!!!!!

    Mogen ze best eens voor simpele zielen zoals ik een leuk PBtje over schrijven dacht ik zo....even een update!
  13. [verwijderd] 28 december 2006 23:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Baar schreef:

    Aossa!

    Thxxx

    Heh! eerst was Crucell nog leuk...nog een beetje bij te houden qua PB's lekkere oplopende koersen.....vandaag te dag gaat het allemaal veel te snel qua ontwikkelingen en de koers te langzaam....

    Je hoort helemaal niets over dat gebouw en de ontwikkelingen in de states waarvan ik dus dacht dat het nog niet eens geopend was....anderhalve maand geleden al....ahum!!!!!!

    Mogen ze best eens voor simpele zielen zoals ik een leuk PBtje over schrijven dacht ik zo....even een update!
    He wunderBAAR,

    Iemand die geinteresseerd is in Crucell is per definitie geen simpele ziel.

    Groet en je eindkoers voor 2007 is......
  15. [verwijderd] 28 december 2006 23:16

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    soldaat schreef:

    [quote=Baar]
    Aossa!

    Thxxx

    Heh! eerst was Crucell nog leuk...nog een beetje bij te houden qua PB's lekkere oplopende koersen.....vandaag te dag gaat het allemaal veel te snel qua ontwikkelingen en de koers te langzaam....

    Je hoort helemaal niets over dat gebouw en de ontwikkelingen in de states waarvan ik dus dacht dat het nog niet eens geopend was....anderhalve maand geleden al....ahum!!!!!!

    Mogen ze best eens voor simpele zielen zoals ik een leuk PBtje over schrijven dacht ik zo....even een update!
    [/quote]

    He wunderBAAR,

    Iemand die geinteresseerd is in Crucell is per definitie geen simpele ziel.

    Groet en je eindkoers voor 2007 is......
    Koers voor mij eind 2007 is......36,14.

    Daar geloof ik echt in! Het nieuwe TomTommetje op de beurs.

    Dit jaar had ik zo rond de 26 euro verwacht.....6,5 euro lager helaas.....dus dan wordt het 29,66????

    En jij?

  16. tegoed 28 december 2006 23:19

    • tegoed

      Lid sinds: 06 mrt 2005

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 35

      Gegeven: 52

    •    Aantal posts: 157

    quote:

    Baar schreef:

    Is het weer voorbij?

    Nou morgen dan maar op de laatste dag van het jaar vuurwerk in de tent!

    Ik vind eerlijk gezegd wel dat we hier een beetje aan toe zijn met zijn allen na maanden van geduld en mooie vooruitzichten die met de dag zelfs mooier worden!!

    Crucell!! Go for it!!
    of.....toch wachten tot dinsdag om de fiscus te pesten !!??
  17. [verwijderd] 28 december 2006 23:21

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    tegoed schreef:

    [quote=Baar]
    Is het weer voorbij?

    Nou morgen dan maar op de laatste dag van het jaar vuurwerk in de tent!

    Ik vind eerlijk gezegd wel dat we hier een beetje aan toe zijn met zijn allen na maanden van geduld en mooie vooruitzichten die met de dag zelfs mooier worden!!

    Crucell!! Go for it!!
    [/quote]
    of.....toch wachten tot dinsdag om de fiscus te pesten !!??
    Geloof ik niet zo; meer om ons te pesten.

    20 K's hebben ze bij mij al weggepest.

    Het jaar 2006???? Om heeeeel erg snel te vergeten! Weg drmee!

    Ik heb in Belgie grote knallers gekocht en die knal ik ook allemaal af!

    De drukker die drukt toch nog wel even door totdat het echt onhoudbaar wordt! Dat gaat m geld kosten! Advies....hij kan beter nu stoppen en ons ook eens een keer wat gunnen. Scheelt heel wat verlies. Een gewaarschuwd mens telt nog altijd voor twee! Eens moet je stoppen een koers af te stoppen als ie straks niet meer te houden is......ik zal zeggen doe hier je voordeel mee en gun ons hetzelfde. Een mooie gedachte voor 2007! Te beginnen: morgen!

    Winst op geschreven calletjes/putjes is niet oneindig.....
  19. [verwijderd] 29 december 2006 00:02

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Baar schreef:

    Flosz nog mooie plaatjes/afbeeldingen over recente ontwikkelingen?
    Per.c6jes en filmpje + linkje pb Percivia:
    www.crucell.nl/downloads/crucell_B-ro...
    cws.huginonline.com/C/132631/PR/20061...
    PER.C6 Human Cell Line

    NOT JUST EVOLUTION
    IT'S A REVOLUTION
    DSM Biologics
    The Future of Human Therapeutics
    www.PERC6.com
    PER.C6® Human Cell Line
    Optimized for Protein & Monoclonal Antibody Production

    The PER.C6® human cell line was created to facilitate biopharmaceutical production such as commercial manufacturing of classical and recombinant vaccines as well as recombinant proteins. High yields, in combination with fully human glycosylation properties, make the PER.C6® human cell line an attractive platform for the production of human proteins, including
    human monoclonal antibodies.
    PERCIVIA, our new PER.C6® Development Center, will specialize in further development of the
    PER.C6® human cell line as the premier platform for the expression of recombinant pharmaceutical
    proteins. This center of excellence will offer a fully integrated technology platform, one that is
    capable of providing turnkey solutions for the production of pharmaceutical proteins to both the
    biotech industry and the scientific community. This comprehensive platform encompasses cell line
    generation technology, cell culture media development, upstream and downstream processes,
    equipment design, scale-up, technology transfer, and regulatory support. PERCIVIA will house
    dedicated staff working in state-of-the-art laboratories with sufficient space to afford
    PER.C6® users a hands-on experience of our technology.
    Biomanufacturing is subject to many changes, such as rising volume demands and increasingly stringent safety requirements. New conditions challenge established methods and make
    the evolution of new manufacturing platforms essential. To be highly adaptable in this environment, DSM and Crucell have formed an alliance that provides a comprehensive platform for biomanufacturing, from cell line generation and the establishment of cell banks to cGMP manufacturing. Combining Crucell’s PER.C6® technology and expertise with DSM’s significant manufacturing infrastructure offers maximum productivity and shortens the time to market for complex biopharmaceuticals.
    The history of PER.C6® cells is an exceptional example of the market’s adaptation to a changing
    environment, both through technology improvements and regulatory stringency. The PER.C6® cell line
    was derived from a single healthy, human retinal cell and recombinant DNA technology allows it to replicate indefinitely. Today, PER.C6® cells provide high yields, industrial level production and human-like glycoforms on expressed proteins.
    With the symbiotic partnership between DSM and Crucell, manufacturing technology and services
    utilizing PER.C6® technology have been expanded.
    Responding to Market Demands with Technological Advancement
    Today’s biopharmaceutical market demands reliable and competitive biomanufacturing Technology—technology that can satisfy high volume needs, stringent safety requirements and ensure manufacturing that is economically feasible.
    For almost 20 years, in vitro production systems have relied on organisms such as bacteria or
    cells isolated almost half a century ago. While yields have increased significantly over two decades with current production systems, no substantive improvement is expected in the next few years. However, the PER.C6® human cell line is designed for protein production, a characteristic that creates opportunities to increase manufacturing yields of monoclonal antibodies and recombinant proteins. PER.C6® technology starts where other systems end.
    In addition, PER.C6® produced proteins have human-like posttranslational modifications that
    may have a positive effect on clinical efficacy and dosing. These characteristics make the PER.C6® cell line the choice for our biotechnology
    and pharmaceutical partners.
    The PER.C6® technology platform eliminates any reason to use dated technologies in an industry focused on technological advancement.
    PER.C6® Technology Advantages
    Rapid Development
    Crucell, DSM and our vendor network have worked
    closely together to offer customers our Phase I/II Shop. This outsourcing option allows customers to develop a serum free, suspension adapted PER.C6® cell line, in three months, and move from a clone to Phase I material in less than 12 months. When your internal resources are tight, use ours.
    Regulatory Acceptance
    Many PER.C6® produced products have been in the
    clinic, with several heading towards Phase III trials. Originally starting in the gene therapy market - which is governed by some of the highest safety standards -PER.C6® produced products have had no adverse reactions reported to date. And with partners such as Merck and Sanofi Pasteur, the regulatory acceptance of PER.C6® products is well established.
    Biologics Master File
    Filed in 1999 with the US FDA, the PER.C6® BMF
    is maintained with annually filed updates. In the BMF, the complete history the PER.C6® cell line is documented like no other cell line, including turmorigencity and assays that go beyond required international guidelines. Licensees to PER.C6® cells can review and 100
    Human-like Glycosylation
    The PER.C6® cell line was isolated from a human
    retinal cell and thus provides human glycosylation
    characteristics. PER.C6®cells are able to naturally produce antibodies that match human physiology.
    PER.C6® products have been used in some of the most
    stringent clinical trials involving the dosing of patients Mass (m/z) and when treatment options are limited. In all cases, not a single adverse event has been documented due Human Serum IgG
    to the use of PER.C6® produced materials.
    High Yields
    For IgG1 monoclonal antibodies, production levels of
    3.5 g/L (and up to 40 pg/cell/day) have been achieved with PER.C6® cells using a standard, generic process that is part of the complete know-how package provided to licensees. Other protein production – such as hormones, enzymes, fusion proteins and others – can also be expressed in PER.C6® cells using methods that have been optimized by Crucell an DSM scientists.
    Serum-free
    PER.C6® cells readily adapt to serum-free conditions
    when your process demands it. Several media
    manufacturers have formulations that have been optimized for PER.C6® cells and are available. When
    the industry began moving toward serum-free production, the PER.C6® cell line was and continues to be at the forefront of these innovations.
    Technology Package
    As a whole product solution, PER.C6® technology
    licensees receive a complete, integrated package
    that enables their product development. Of note is
    a comprehensive array of protocols for PER.C6® cell
    technology that can address any product development
    path you may be pursuing. Licensees also have
    access to the PER.C6® extranet for continuous
    updates of new and archived methods. Additional
    technical support is also available through us: just call us with your questions and we are ready to help.
    Flexible License Arrangements
    Obtaining PER.C6® technology has never been easier.
    With flexible license structures for pure evaluation up through commercial rights, we can work with you
    to ensure that the right fit of PER.C6® technology is provided for your particular product, company position, and future goals.
    Bijlage:
120 Posts
Pagina: «« 1 2 3 4 5 6 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.483
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.206
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.528
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.651
Aedifica 3 901
Aegon 3.258 322.670
AFC Ajax 538 7.086
Affimed NV 2 6.288
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.294
Air France - KLM 1.025 35.000
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.334
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.813
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.759
AMG 971 133.102
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 485
Antonov 22.632 153.605
Aperam 92 14.936
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.583
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.716
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.082
ASML 1.766 106.069
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 470
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390